methyl anthranilate has been researched along with vx-770 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baettig, U; Bahra, P; Bala, K; Brocklehurst, C; Budd, E; Butler, R; Cheung, AK; Choudhury, H; Collingwood, SP; Cox, B; Danahay, H; Edwards, L; Everatt, B; Glaenzel, U; Glotin, AL; Gosling, M; Grand, DL; Groot-Kormelink, P; Hall, E; Hatto, J; Howsham, C; Hughes, G; King, A; Koehler, J; Kulkarni, S; Lightfoot, M; Nicholls, I; Page, C; Pergl-Wilson, G; Popa, MO; Robinson, R; Rowlands, D; Sandham, DA; Sharp, T; Spendiff, M; Stanley, E; Steward, O; Taylor, RJ; Tranter, P; Wagner, T; Watson, H; Williams, G; Wright, P; Young, A | 1 |
1 other study(ies) available for methyl anthranilate and vx-770
| Article | Year |
|---|---|
Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
Topics: Administration, Oral; Aminopyridines; Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Models, Animal; Drug Evaluation, Preclinical; Gene Deletion; Half-Life; Humans; Protein Binding; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Sprague-Dawley; Solubility; Structure-Activity Relationship | 2021 |